Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
In DMSO RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献137篇:

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NITWTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wVGR{PzJiaB?= NH7DRnhFVVOR NX72VoZuUUN3ME2wMlAxODB5IN88US=> NGPtSZcyPzl3NkC4NC=>
K562 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi3NkBp NXnuTmNmTE2VTx?= NYjF[FJXUUN3ME2wMlAxOSEQvF2= MkTrNVc6PTZyOEC=
M07e NYT0XGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnpOGZ2PzJiaB?= NWrqdpBPTE2VTx?= MkDOTWM2OD1yLkCwNVIh|ryP M3;GUFE4QTV4MEiw
ALL3 MVHDfZRwfG:6aXOgRZN{[Xl? NV7QNHhQOC5zzszN M17n[|czKGh? MmCySG1UVw>? MUXJR|UxRTBwMECwOEDPxE1? M4XifVE6QDh7NUSw
CML NIXjOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHXPHVwOjBibXnu M2HSTGROW09? NW\WW|k{UUN3ME2wMlAxOSEQvF2= M3LxWFE6OjF7MEG2
BA/F3 M3;2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYW3NkBp M2fjfWROW09? NFn3XYtKSzVyPU[uOVg6KM7:TR?= M1;4V|I{ODh6NkS0
BA/F3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\LVZRwPzJiaB?= MXnEUXNQ NW\5RZF5UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> M2DtelI{ODh6NkS0
BA/F3 M1j1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXVZWk1PzJiaB?= MoLOSG1UVw>? MUDJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO NGj5NmQzOzB6OE[0OC=>
BA/F3 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO3NkBp M4X2XGROW09? MULJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? MoHENlMxQDh4NES=
BA/F3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HJ[VczKGh? M{[xUmROW09? MYLJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? Ml3kNlM{ODF5MEO=
BA/F3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP6SnNjPzJiaB?= M{PZXWROW09? NFLseXBKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= M2KzcFI{OzBzN{Cz
BA/F3 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzWO|IhcA>? NV7ofmp{TE2VTx?= MVPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? NVu0Uo5lOjN|MEG3NFM>
BA/F3 NXju[HFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HJNFczKGh? M1WwSGROW09? MV3JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO MXuyN|MxOTdyMx?=
BA/F3 M3KyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvYO|IhcA>? MYTEUXNQ MWnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? MoHvNlM{ODF5MEO=
BA/F3 NFrnZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXyO|IhcA>? NVizZVVZTE2VTx?= MXjJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> MmHGNlM{ODF5MEO=
BA/F3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\KVlc4OiCq NEDJZnlFVVOR NUHUd4s4UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2= MmfTNlM{ODF5MEO=
BA/F3 M2XFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfyO|IhcA>? NWH1WXljTE2VTx?= MXvJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> M2XPdlI{OzBzN{Cz
BA/F3 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;tVVY4OiCq M4Hw[WROW09? NVPwb3RTUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN NFrYe2UzOzNyMUewNy=>
T cell MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXjO|IhcA>? M3v0U2ROW09? NHnJU|lKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>? MWmxO|E2PDVzMh?=
WiDr NUSx[pVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTuO|IhcA>? NYqzcXZ7TE2VTx?= M2H5NGlEPTB;MD6wOVIh|ryP MVmxOVYyPTVzMh?=
PC3 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3vZZB3PzJiaB?= NV21O4tWTE2VTx?= MYXJR|UxRTBwMEC5OEDPxE1? NITQUYoyPTZzNUWxNi=>
MDA-MB-231 MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zUTFczKGh? MV;EUXNQ NXTlbXBwUUN3ME2wMlAyOiEQvF2= NVXaXm5YOTV4MUW1NVI>
Hs578T Mkn0R5l1d3SxeHnjJGF{e2G7 M1;4OlczKGh? NF3SZ21FVVOR MUTHTVUxRTBwMEOg{txO NHHRZ4czPDBzNUOyOy=>
HMEC MkXpR5l1d3SxeHnjJGF{e2G7 NWXU[mF[PzJiaB?= MnXlSG1UVw>? NFPhXHhIUTVyPUGuPEDPxE1? NIPJcJIzPDBzNUOyOy=>
DU145 MWnDfZRwfG:6aXOgRZN{[Xl? MmnxO|IhcA>? MmPJSG1UVw>? M3nweGdKPTB;MD6xOkDPxE1? MmPXNlQxOTV|Mke=
U251 NV20bYNqS3m2b4TvfIlkKEG|c3H5 MYW3NkBp NY[zNnVTTE2VTx?= MmDZS2k2OD1{LkixJO69VQ>? MnPsNlQxOTV|Mke=
NCI60 MnPvR5l1d3SxeHnjJGF{e2G7 NWDwW|BJPzJiaB?= NEjyN2NFVVOR MUHHTVUxRTVwNzFOwG0> MUmyOFAyPTN{Nx?=
MALME-3M MlvYR5l1d3SxeHnjJGF{e2G7 NGDmSFI4OiCq NYPIPVNnTE2VTx?= MVzHTVUxRTZwNkGg{txO M4rKVVI1ODF3M{K3
KM12 MYjDfZRwfG:6aXOgRZN{[Xl? NFPuUpU4OiCq NHfCeIVFVVOR NFPkZpJIUTVyPUeuOFQh|ryP M1rDXlI1ODF3M{K3
SW620 M1\hOWN6fG:2b4jpZ{BCe3OjeR?= MmLmO|IhcA>? MnzpSG1UVw>? NYTKfVhJT0l3ME24MlQ{KM7:TR?= MWeyOFAyPTN{Nx?=
RXF 393NL Ml;JR5l1d3SxeHnjJGF{e2G7 MkjWOEBl[Xm| MkP0SG1UVw>? NH3adpVKSzVyPUCuNFIyPyEQvF2= NGW4RYozOzJ3M{C3OC=>
LXFA 983L MULDfZRwfG:6aXOgRZN{[Xl? MYq0JIRigXN? M4OwW2ROW09? Mn3kTWM2OD1yLkC1OlUh|ryP MVKyN|I2OzB5NB?=
PRXF DU145 NHfIRnFEgXSxdH;4bYMhSXO|YYm= Mm[4OEBl[Xm| NGjp[olFVVOR NFj6OFdKSzVyPUCuNFYzOyEQvF2= MkjMNlMzPTNyN{S=
PAXF 1657L MVzDfZRwfG:6aXOgRZN{[Xl? MYq0JIRigXN? NGq3NGFFVVOR NEfFRVFKSzVyPUCuNVIyKM7:TR?= NHzlVWczOzJ3M{C3OC=>
CXF 1103L MXvDfZRwfG:6aXOgRZN{[Xl? NEH1d4s1KGSjeYO= MkHxSG1UVw>? MoC4TWM2OD12LkO2JO69VQ>? MkmzNlMzPTNyN{S=
GXF251L NUm2V3RIS3m2b4TvfIlkKEG|c3H5 NXK1[XNGPCCmYYnz Mkm3SG1UVw>? M4iyNGlEPTB;Mj6yOUDPxE1? M{W1WFI{OjV|MEe0
NCI-H23 M1L1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUK3NkBp M3vpe2ROW09? MW\JR|UxRTJwMkeg{txO NHLueoczOzV{MUCyNC=>
HCT116 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W5SFczKGh? MXTEUXNQ NUOzXYpNUUN3ME2yMlMh|ryP Mn7qNlM2OjFyMkC=
MCF7 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGxO|IhcA>? NXXpeHBqTE2VTx?= M2PoVmlEPTB;Mj61O{DPxE1? NF32fVAzOzV{MUCyNC=>
NCI-H460 NIP4ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLwe5A4OiCq M4nCPWROW09? MoHqTWM2OD16Lkm5JO69VQ>? Ml;kNlM2OjFyMkC=
DLD1 MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfJPHQ{PzJiaB?= NYfofGQ{TE2VTx?= NWrOcHFvUUN3ME20MlYh|ryP NFTIfnEzOzV4N{m2NC=>
NCI-H661 NFTZ[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW3NkBp NWjMWXJxTE2VTx?= NG[0dJRKSzVyPUeuPEDPxE1? NGnTfJgzOzV4N{m2NC=>
A549 NVnOXm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLWOHd[PzJiaB?= NIjPNo5FVVOR MYjJR|UxRThwMjFOwG0> MYOyN|U3Pzl4MB?=
U937 M2DjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnJPZFvPzJiaB?= M{fiW2ROW09? MlLXTWM2OD1zMj6yJO69VQ>? NWGxXZJlOjN3Nke5OlA>
HEK293 NF7BVHlHfW6ldHnvckBCe3OjeR?= M1HNPFExyqEQvF2= NUj4Zpl[TE2VTx?= MY\JcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= M{LFOlIzPzdyNkGw
HUVEC NH\jSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XLXVAvOTYEoN88US=> NX3aZm42PzJiaB?= NWrscZNsTE2VTx?= MWXJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= NV7xc3FwOjJ6NUO5PVM>
HUVEC Ml;LSpVv[3Srb36gRZN{[Xl? NIrEUFAyPcLizszN M3i3bFczKGh? M3jvRWROW09? NUnMS3VtUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? NVz2eJNUOjJ6NUO5PVM>
Plasmodium falciparum M3vHWWZ2dmO2aX;uJGF{e2G7 M{XxbVExyqEQvF2= NVL5WYN{OTVibXnu NXLY[Is1TE2VTx?= MVXJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0> MVqyOFU2ODN|MB?=
PC3 Mn2xSpVv[3Srb36gRZN{[Xl? MV[wMlEh|ryP M3myU|UhcA>? M1HRTmROW09? MWLJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1? NFXUc3UyQTR4Mkm3OS=>
DU145 MVjGeY5kfGmxbjDBd5NigQ>? MVOwMlEh|ryP MnnXOUBp NUDIUpV6TE2VTx?= NFPOSo1KdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> M3LiWVE6PDZ{OUe1
PC3 M3n6OGtqdmG|ZTDBd5NigQ>? MlGyNE4yKM7:TR?= MYW1JIg> NYLFcmFiTE2VTx?= MX3Jcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P NHzmdVAyQTR4Mkm3OS=>
DU145 NFHRXo1McW6jc3WgRZN{[Xl? NGXHWYgxNjFizszN NH7i[2E2KGh? M3HpSmROW09? NX3tdWoyUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O NWXKbJRVOTl2NkK5O|U>
PC3 NGXDN4VMcW6jc3WgRZN{[Xl? NFe2c2cxNjFizszN MmPSOUBp NHztPHlFVVOR M1L4U2lvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NVP5cpVMOTl2NkK5O|U>
DU145 NFewWoxMcW6jc3WgRZN{[Xl? M2jSW|AvOSEQvF2= MUK1JIg> MV;EUXNQ M{fER2lvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P M2HaelE6PDZ{OUe1
Huh7 NXzsOoNtSW62aY\pdoFtKEG|c3H5 Ml3yNk42KM7:TR?= MonQOEBl[Xm| NHjBR3FFVVOR M{jOe2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= MWixO|M3ODZ5Nh?=
C6/36 NHH2cm1CdnSrdnnyZYwhSXO|YYm= Mlj4Nk42KM7:TR?= NWn5XlBVPCCmYYnz NED6eo5FVVOR NFznfpFKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP MmfLNVc{PjB4N{[=
U937 MkjUSpVv[3Srb36gRZN{[Xl? MUKxJO69VQ>? MlH1NUBp MojaSG1UVw>? NH3BTI9T\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?= NGX6d|EyPzZ6NEC5PS=>
U937 NFX1SVBHfW6ldHnvckBCe3OjeR?= M33Hb|Eh|ryP NX3NSHpUOSCq MnjuSG1UVw>? MXLS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> MX[xO|Y5PDB7OR?=
murine mast cell MkD3SpVv[3Srb36gRZN{[Xl? NGr5d2QyKM7:TR?= MVqyOEBp Mm\NSG1UVw>? MWPJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? MYmxO|Y5PDB7OR?=
BV-173 M3\wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX3TWM2OD1yLkCwNFAxODFyOTFOwG0> MoW0V2FPT0WU
K-562 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SzR2lEPTB;MD6wNFAxODB{Nk[g{txO M3XNTHNCVkeHUh?=
BL-70 NVmyVWhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnlSWsyUUN3ME2wMlAxODByMEiyNkDPxE1? MY\TRW5ITVJ?
EM-2 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMECwNFAyODhizszN NV\JXJc6W0GQR1XS
LAMA-84 NXjZVHlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMECwNFA{OjFizszN MoO5V2FPT0WU
MEG-01 NFvnXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWzTWM2OD1yLkCwNFAxQThizszN M2jROnNCVkeHUh?=
EoL-1-cell MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMECwNFE{OSEQvF2= NIXrRZpUSU6JRWK=
CTV-1 M2Ph[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHHW49KSzVyPUCuNFAxODRyNDFOwG0> NHjjSWhUSU6JRWK=
TE-15 M2TqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f5[GlEPTB;MD6wNFU5QSEQvF2= M3jDbHNCVkeHUh?=
NOS-1 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP0fplpUUN3ME2wMlAxPjF|IN88US=> NUXuflBkW0GQR1XS
D-336MG NEC0S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnVdmExUUN3ME2wMlAxPjNizszN NEWwNoRUSU6JRWK=
LB1047-RCC NYfoU|dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMEC5PFkh|ryP NFXFfIdUSU6JRWK=
LB996-RCC Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPQSolKSzVyPUCuNFA6QTFizszN Mn;lV2FPT0WU
SW982 NV;NdYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17DTWlEPTB;MD6wNVEyPSEQvF2= NH7nWJpUSU6JRWK=
TK10 M2L3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXUXVZrUUN3ME2wMlAyOTd2IN88US=> MlXTV2FPT0WU
A704 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEG0PVEh|ryP NUPRbIk2W0GQR1XS
TE-8 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEG1O|Yh|ryP NFm2eW1USU6JRWK=
DOHH-2 NUPvV4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEG3NVkh|ryP NIDjbHJUSU6JRWK=
HOP-62 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LXfGlEPTB;MD6wNVg{PCEQvF2= MWLTRW5ITVJ?
TE-12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fvN2lEPTB;MD6wNVg3OSEQvF2= NVizSo94W0GQR1XS
KGN NX\xOHZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHFZ|FKSzVyPUCuNFE6PDJizszN MnXxV2FPT0WU
NCI-H1648 M1XwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLYTWM2OD1yLkCyNFEyKM7:TR?= MlfiV2FPT0WU
OS-RC-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\oO3p7UUN3ME2wMlAzODNizszN NYfZ[nZOW0GQR1XS
GB-1 NFq4bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEKxOVch|ryP NXL3XY9EW0GQR1XS
RXF393 M371Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDDRlZLUUN3ME2wMlAzOzV5IN88US=> NUn6Z5BoW0GQR1XS
LC-2-ad MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXxT49KSzVyPUCuNFI2QDZizszN MlKzV2FPT0WU
KS-1 M3\MXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TiNmlEPTB;MD6wNlc{KM7:TR?= NXWyTIhOW0GQR1XS
ETK-1 NEHtR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXo[YNKSzVyPUCuNFI5OzJizszN M3rTPXNCVkeHUh?=
SW954 NGXzPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj2UGV5UUN3ME2wMlAzQTJ5IN88US=> MkOwV2FPT0WU
Becker NHnXUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS1WoJWUUN3ME2wMlA{ODB|IN88US=> NWLjc4dCW0GQR1XS
MZ1-PC MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LnXmlEPTB;MD6wN|EyQSEQvF2= MX3TRW5ITVJ?
ES6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV63bnh4UUN3ME2wMlA{OTl|IN88US=> NFrDOJRUSU6JRWK=
KURAMOCHI NYTofFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEO0PFch|ryP MUfTRW5ITVJ?
CGTH-W-1 NYnZZVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zCS2lEPTB;MD6wN|U1QCEQvF2= MnL4V2FPT0WU
VA-ES-BJ MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7uc|ZQUUN3ME2wMlA{QTB{IN88US=> NYPySZVWW0GQR1XS
LXF-289 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jNdWlEPTB;MD6wN|k2PiEQvF2= NYX6Zmh6W0GQR1XS
MPP-89 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELY[nFKSzVyPUCuNFQxPDlizszN MV;TRW5ITVJ?
SW872 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7VeHY1UUN3ME2wMlA1OTZzIN88US=> MVvTRW5ITVJ?
SNB75 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\DbJlKSzVyPUCuNFQ1OzVizszN M2jObHNCVkeHUh?=
PSN1 MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LFWmlEPTB;MD6wOFQ4PCEQvF2= Mn60V2FPT0WU
LB831-BLC NV;OXoxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO1TWM2OD1yLkC0OlA6KM7:TR?= MVPTRW5ITVJ?
MFH-ino NGXTU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK5OmdKSzVyPUCuNFQ4OjRizszN NHHaO4NUSU6JRWK=
TGBC24TKB M4DrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjudYxKSzVyPUCuNFQ4PjFizszN MlnsV2FPT0WU
A388 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHBfo5KSzVyPUCuNFUxQTVizszN MkexV2FPT0WU
BB30-HNC NVXCc3VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX1VXZSUUN3ME2wMlA2PDN5IN88US=> M3LNRXNCVkeHUh?=
GI-ME-N MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe4b|NKSzVyPUCuNFYyOThizszN MnPsV2FPT0WU
TGBC1TKB NVfsZlRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuTWM2OD1yLkC2NVY1KM7:TR?= NGL6SIJUSU6JRWK=
TE-10 M4rueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPYV2lKSzVyPUCuNFY{PTdizszN MnvCV2FPT0WU
A498 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEiyT3NKSzVyPUCuNFczQDRizszN MmnJV2FPT0WU
TE-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzkb4JKSzVyPUCuNFc5PThizszN M2HNcnNCVkeHUh?=
BB65-RCC NX7obIdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HlR2lEPTB;MD6wPFIzPyEQvF2= NET1dYhUSU6JRWK=
C2BBe1 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XMfmlEPTB;MD6wPFMxQCEQvF2= NXTrToFGW0GQR1XS
NCI-H747 NVn3[|ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;ofGlEPTB;MD6wPFM3OiEQvF2= NUixV5ltW0GQR1XS
IST-MES1 NVrhV5ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWOweGlHUUN3ME2wMlA5PTV{IN88US=> MVXTRW5ITVJ?
KALS-1 MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HJcWlEPTB;MD6wPVQ6KM7:TR?= MUDTRW5ITVJ?
GCIY NYr6XpgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEm2OVYh|ryP NU\Be|VmW0GQR1XS
RL95-2 M3Lwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzFV4hsUUN3ME2wMlExOzhizszN NWj3ZlZyW0GQR1XS
TE-1 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XxNGlEPTB;MD6xNFU1KM7:TR?= MYfTRW5ITVJ?
NCI-H1355 MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzPVopmUUN3ME2wMlEyODJ6IN88US=> MYTTRW5ITVJ?
SW962 M{D4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3kVnF{UUN3ME2wMlEyOjl{IN88US=> M3HCR3NCVkeHUh?=
KLE MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX71V|V6UUN3ME2wMlEyOzF5IN88US=> MYnTRW5ITVJ?
MC116 Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDwSVBKSzVyPUCuNVE1OSEQvF2= NEm4Z49USU6JRWK=
NMC-G1 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfzfWh5UUN3ME2wMlEyPjB4IN88US=> NGTNe5JUSU6JRWK=
KU812 M3PPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTCTWM2OD1yLkGxPFg{KM7:TR?= M37MdnNCVkeHUh?=
COLO-829 NVjuOGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fWTGlEPTB;MD6xNlIyOyEQvF2= Mk\5V2FPT0WU
NTERA-S-cl-D1 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPTTWM2OD1yLkGyNlg{KM7:TR?= NYDlSZplW0GQR1XS
IST-MEL1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH24d3BKSzVyPUCuNVM1PSEQvF2= MmLFV2FPT0WU
MLMA NYXnVpZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vzWmlEPTB;MD6xOFA{OiEQvF2= MkPOV2FPT0WU
LS-123 M1XCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHIdVRKSzVyPUCuNVQxPjRizszN NXy0VG5EW0GQR1XS
LB2518-MEL NHTnbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WzS2lEPTB;MD6xOFE3OiEQvF2= MkPWV2FPT0WU
NB69 NXzKSVdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMUS0N|Yh|ryP MXzTRW5ITVJ?
8-MG-BA M{HTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMUW0OVgh|ryP NIHB[VBUSU6JRWK=
K5 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrHTWJKSzVyPUCuNVY1QDlizszN MVnTRW5ITVJ?
KINGS-1 NH\wdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnGRZpKSzVyPUCuNVY3PjZizszN M1jaT3NCVkeHUh?=
SF268 M13Rb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\0TWM2OD1yLkG3OFA1KM7:TR?= NGK3TVZUSU6JRWK=
PF-382 NIjze2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMUe2O|gh|ryP MWrTRW5ITVJ?
SH-4 NXT2XWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\POGp4UUN3ME2wMlE5PDF|IN88US=> NV\Vc3NkW0GQR1XS
NALM-6 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[4TWM2OD1yLkG5Nlk2KM7:TR?= MV7TRW5ITVJ?
CP66-MEL NXjBcY9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n3XGlEPTB;MD6xPVU{OSEQvF2= MV3TRW5ITVJ?
697 NEizemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUm5PFch|ryP MlriV2FPT0WU
CP67-MEL M4LXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HKRmlEPTB;MD6yNFQ5QCEQvF2= M1nxXHNCVkeHUh?=
DSH1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP6TWM2OD1yLkK0NFAyKM7:TR?= NWDPRXZQW0GQR1XS
HCE-4 NHHqemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LrO2lEPTB;MD6yOlQ{QSEQvF2= MWLTRW5ITVJ?
MZ2-MEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;yXFA4UUN3ME2wMlI5PTN5IN88US=> M4PBPHNCVkeHUh?=
BL-41 NIf0b25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMkmxNlMh|ryP NH\kOldUSU6JRWK=
HUTU-80 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwM{G0NkDPxE1? NULMfGpOW0GQR1XS
LOXIMVI MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XQVmlEPTB;MD6zNVUxOyEQvF2= MnrFV2FPT0WU
no-10 NYTUfYZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwM{G5N|Eh|ryP M3XiZXNCVkeHUh?=
KARPAS-422 NYfBOJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm4OYhKSzVyPUCuN|M6QTdizszN MmLkV2FPT0WU
SW684 M2\XbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrteZVKSzVyPUCuN|Q6QCEQvF2= NELaN5pUSU6JRWK=
SF126 NXT4fnBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;MTWM2OD1yLkO1OFEh|ryP MoG0V2FPT0WU
D-263MG MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLJNm96UUN3ME2wMlM3OjJ2IN88US=> M1XQ[XNCVkeHUh?=
OVCAR-4 M2LoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPsd3JKSzVyPUCuN|c1OzNizszN NHfkdFhUSU6JRWK=
BB49-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf6SoZKSzVyPUCuN|g2QTlizszN NVzBU29XW0GQR1XS
ONS-76 NYnnb|B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTZNXR7UUN3ME2wMlQzQTVzIN88US=> MWXTRW5ITVJ?
MZ7-mel NWToNFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPBTWM2OD1yLkS3PVEyKM7:TR?= NGLycGNUSU6JRWK=
RCC10RGB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LXUWlEPTB;MD60PVEyKM7:TR?= NVHOdnZYW0GQR1XS
BOKU NGDpN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDyNGZKSzVyPUCuOFkyOzNizszN NIL5doJUSU6JRWK=
no-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwNUCyNlgh|ryP MkT5V2FPT0WU
IST-SL2 M4\q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jKb2lEPTB;MD61NFMxOiEQvF2= NHPjc5pUSU6JRWK=
RKO NEfYcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvRTWM2OD1yLkWyPVY3KM7:TR?= NFTIcHJUSU6JRWK=
HT-144 NHHTVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13ESWlEPTB;MD61N|YxQSEQvF2= NF\xWXNUSU6JRWK=
NCI-H446 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXkeJZGUUN3ME2wMlYzPzZizszN M37aN3NCVkeHUh?=
QIMR-WIL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\obYxKSzVyPUCuO|A3OjlizszN NVrpO4xoW0GQR1XS
MHH-PREB-1 M3nFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGryO25KSzVyPUCuO|Q1PjlizszN MUPTRW5ITVJ?
EW-16 NVjvblBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwN{[xO|gh|ryP NFzYVG5USU6JRWK=
EW-24 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwN{ixOlUh|ryP NH\W[3pUSU6JRWK=
LB373-MEL-D M1q2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\nTWM2OD1yLkiyOVA5KM7:TR?= MkPvV2FPT0WU
TE-9 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwOEe1N|Ih|ryP M{T1cnNCVkeHUh?=
A3-KAW M{nPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwOUi0OVIh|ryP NYH5VlN5W0GQR1XS
A101D NVX6d4VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjCbnRKSzVyPUGuNFMxPDNizszN NETFOHdUSU6JRWK=
OCUB-M NXi3fFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\yTWM2OD1zLkC0OFEzKM7:TR?= NEjIfFFUSU6JRWK=
ES4 NInrdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwMEWxOFUh|ryP MlPzV2FPT0WU
TE-6 NIrZ[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\IeWpKSzVyPUGuNlEzOjZizszN M{DheHNCVkeHUh?=
D-502MG MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFwMkOzO|Yh|ryP M2jhe3NCVkeHUh?=
KNS-42 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrzbWJKSzVyPUGuNlQ1OTJizszN M3;JcXNCVkeHUh?=
SNU-C2B NVfpNW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTZTWM2OD1zLkOwOVg6KM7:TR?= MVLTRW5ITVJ?
NCI-H1838 M3vONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDqXoF2UUN3ME2xMlMxPzN|IN88US=> M1;n[HNCVkeHUh?=
NKM-1 NInqOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwM{C4OVkh|ryP MoHLV2FPT0WU
GI-1 M3jyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XCfGlEPTB;MT6zOlIzKM7:TR?= MX;TRW5ITVJ?
NB5 M3vnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHFSZRKSzVyPUGuN|k5OjdizszN NIfCe4FUSU6JRWK=
CAS-1 M1HMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqxcJlKSzVyPUGuOFA6QTJizszN M3\Ec3NCVkeHUh?=
HCE-T M3zuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfLb4JDUUN3ME2xMlU3PzF2IN88US=> NVzQUZhxW0GQR1XS
SBC-1 NEXpZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXUc|VKSzVyPUGuOVc6QDRizszN M3TUXXNCVkeHUh?=
JiyoyeP-2003 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7UXo1vUUN3ME2xMlc{PDZ4IN88US=> NXqwfoxpW0GQR1XS
TE-5 M1n2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHoTWM2OD1zLke5NVM6KM7:TR?= NGLGR4xUSU6JRWK=
CAN MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fNcGlEPTB;MT64NlI2OiEQvF2= M4ruPXNCVkeHUh?=
SK-UT-1 NVXxXms{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jLS2lEPTB;Mj6xOlY6OyEQvF2= NGnkSYhUSU6JRWK=
JVM-2 M2PwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\VTWM2OD1{LkO2Nlg1KM7:TR?= NYDqdHRiW0GQR1XS
LB771-HNC NITwbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzXVldyUUN3ME2yMlU4PTVzIN88US=> Mk\DV2FPT0WU
NCCIT NWfnTHU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHKcmlKSzVyPUKuPFY3OTZizszN MUnTRW5ITVJ?
NCI-H2126 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDh[lJKSzVyPUKuPFc2PTJizszN MX3TRW5ITVJ?
Calu-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNwMEW3OFEh|ryP NELBbJFUSU6JRWK=
SK-LMS-1 NUDSVpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmzW2RKSzVyPUOuNVE5QDZizszN M2PzcHNCVkeHUh?=
ARH-77 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;zTmlEPTB;Mz60OlkyPSEQvF2= MnHPV2FPT0WU
NB17 NGrESIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XzNGlEPTB;Mz62N|g1PyEQvF2= MnTRV2FPT0WU
A253 NHHsWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPXSnBQUUN3ME2zMlc{OjR4IN88US=> NUnYV4o1W0GQR1XS
OPM-2 NXG4OZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTRwMke2PFUh|ryP MV7TRW5ITVJ?
MV-4-11 M2fxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LGeWlEPTB;ND6zOlQ2PCEQvF2= MY\TRW5ITVJ?
SR NULtNoU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCwTWM2OD12LkS5PVU1KM7:TR?= Ml3VV2FPT0WU
KG-1 NFjkTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f2W2lEPTB;ND62NFg1PSEQvF2= NGmwellUSU6JRWK=
OCI-AML2 NX74XZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzzTWM2OD13Lki2NVU1KM7:TR?= NFzvWnZUSU6JRWK=
D-247MG M3zETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfNTWM2OD14LkGyOVE6KM7:TR?= Mof3V2FPT0WU
DJM-1 NYDUN|l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTZwNEi1OVgh|ryP NH\RcG1USU6JRWK=
RPMI-6666 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTRTFZoUUN3ME23MlI4ODZ5IN88US=> Mlj6V2FPT0WU
KARPAS-45 M1rwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTdwNUG2O|Eh|ryP NFjncpdUSU6JRWK=
LP-1 NI\MfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTdwNUS3PFIh|ryP MkDXV2FPT0WU
RS4-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFTnp5UUN3ME23MlY2Pzh5IN88US=> MmLZV2FPT0WU
DU-4475 NFiyR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjzSWVSUUN3ME24MlIyPjV{IN88US=> Mn7tV2FPT0WU
MONO-MAC-6 MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLsdIt{UUN3ME24MlI4ODZ4IN88US=> NU\qeWlZW0GQR1XS
NCI-SNU-16 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInlN2FKSzVyPUiuOVYyOjhizszN M4fvdXNCVkeHUh?=
SJSA-1 M4rHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRThwN{K4NFUh|ryP NYPLOoM6W0GQR1XS
MMAC-SF Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;tTWM2OD16Lke5N|A4KM7:TR?= NUHaNmNVW0GQR1XS
SK-NEP-1 NHXGbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3hTWM2OD16Lki5NVU2KM7:TR?= MmHBV2FPT0WU
J-RT3-T3-5 NG\a[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRThwOU[1Nlkh|ryP Mn\NV2FPT0WU
SKM-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknrTWM2OD17LkCxO|M1KM7:TR?= NH:ydIlUSU6JRWK=
LB2241-RCC M4e1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHqdYZmUUN3ME25MlAzODF{IN88US=> NFTZcIpUSU6JRWK=
SIG-M5 NYD1dHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTlwMEK0PVMh|ryP MlqwV2FPT0WU
EVSA-T NYGzXWZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH0WldKSzVyPUmuNlc4QTNizszN MmT4V2FPT0WU
GT3TKB MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jISWlEPTB;OT6zOVU1PiEQvF2= NX3UeVU4W0GQR1XS
NB6 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTlwOUKyOVkh|ryP M{PQb3NCVkeHUh?=
EHEB NVHpS41rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTtOoZ5UUN3ME2xNE4xPjV4IN88US=> M2[4e3NCVkeHUh?=
HEL NXf1TnRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFyLkS3O|Yh|ryP MojKV2FPT0WU
ALL-PO M4j3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rlcGlEPTB;MUCuO|k{QCEQvF2= M4nuc3NCVkeHUh?=
TGW NHHxXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PRSmlEPTB;MUGuNlgzQCEQvF2= MVTTRW5ITVJ?
BC-3 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vBd2lEPTB;MUKuNVE{QCEQvF2= M3HWc3NCVkeHUh?=
IA-LM NGi3e3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF{LkS0OFUh|ryP MX3TRW5ITVJ?
UACC-257 NV7N[4pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zkSWlEPTB;MUKuPVE6QCEQvF2= MVfTRW5ITVJ?
KP-N-YS NFm1N4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\3NGlEPTB;MUKuPVI5OyEQvF2= NIe3XHdUSU6JRWK=
Raji NIi1bllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS1TWM2OD1zMz63OFk4KM7:TR?= M1f5e3NCVkeHUh?=
SF539 NUKxb2g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLpNoNnUUN3ME2xN{45PTV5IN88US=> NX3hfnZJW0GQR1XS
DMS-153 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF2LkCwNlgh|ryP MnL2V2FPT0WU
L-540 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\UT2lEPTB;MUWuNFY4OiEQvF2= MX3TRW5ITVJ?
MN-60 Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonUTWM2OD1zNT6xPVc6KM7:TR?= NWXuTW1YW0GQR1XS
RPMI-8866 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD2TWM2OD1zNz60OFU1KM7:TR?= NGnMXZlUSU6JRWK=
NCI-H510A NVfYdmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13Q[mlEPTB;MUmuN|k4OyEQvF2= MXzTRW5ITVJ?
NB13 NUfaNHZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW2TWM2OD1zOT60PFc4KM7:TR?= MUfTRW5ITVJ?
HAL-01 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXRTWM2OD1zOT63OVQ{KM7:TR?= MWPTRW5ITVJ?
NCI-H720 M{XycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzzTGp4UUN3ME2yNE4zPzN|IN88US=> NH7jTnlUSU6JRWK=
REH M1fNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\LTWM2OD1{MD62N|U4KM7:TR?= MVTTRW5ITVJ?
KNS-81-FD NFLR[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;xTWM2OD1{Mz6xOFYh|ryP MVjTRW5ITVJ?
HC-1 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ2LkW1OVEh|ryP NXP3Xo1bW0GQR1XS
NCI-H2141 NFjJdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\1PJN1UUN3ME2yOE44PzV2IN88US=> Mnn1V2FPT0WU
MOLT-4 M33UPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnwXXZKSzVyPUK2MlY4PTNizszN NFGxdmRUSU6JRWK=
OMC-1 M3rHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJ5LkG0NlIh|ryP MYLTRW5ITVJ?
LC-1F Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrtTWM2OD1{Nz6zNlQ2KM7:TR?= M{LHcnNCVkeHUh?=
NCI-H1304 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fYbWlEPTB;MkiuNVYzQCEQvF2= NHjRNIhUSU6JRWK=
BC-1 NHrzOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;nWW9oUUN3ME2yPE43PTFizszN NVH2ZWd6W0GQR1XS
NCI-H64 M4TT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonoTWM2OD1{OT62NlU{KM7:TR?= MoOwV2FPT0WU
MOLT-16 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7kPJlKSzVyPUK5MlYzQTJizszN MWTTRW5ITVJ?
U-87-MG NYOxVYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED6VZJKSzVyPUOwMlc3PiEQvF2= MUTTRW5ITVJ?
GAK NV[3[lUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNzLkK2PFYh|ryP MYXTRW5ITVJ?
ES8 NYnx[GhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\wU5FqUUN3ME2zNk4yOjV{IN88US=> MXvTRW5ITVJ?
HCC1599 M2TTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLqTWM2OD1|Mj6zN|I2KM7:TR?= NVnJT|BkW0GQR1XS
EB-3 NEDpWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN2LkOxNVch|ryP MlrSV2FPT0WU
HCC1187 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrvbZVIUUN3ME2zOU45ODV{IN88US=> NITiXGRUSU6JRWK=
SK-PN-DW MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPlcXduUUN3ME2zOk4yQTR|IN88US=> MXHTRW5ITVJ?
JVM-3 M4nwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTN5LkKzN|gh|ryP M17PWHNCVkeHUh?=
HCC2157 NHfDeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PCbWlEPTB;M{euPVk1PiEQvF2= NXnvbVN[W0GQR1XS
A4-Fuk M1f3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\DS2lEPTB;M{iuNVAxQSEQvF2= M2TibnNCVkeHUh?=
COR-L279 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnhSGFKSzVyPUSwMlI5PTFizszN NUTldXV7W0GQR1XS
DEL M2L6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG3TWM2OD12MT65NFg3KM7:TR?= MVHTRW5ITVJ?
NCI-H1395 NIn5[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[0V2ZKSzVyPUSyMlAyPjNizszN NWnBSoRFW0GQR1XS
MHH-NB-11 M{GyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTR|LkC4NVgh|ryP MnTBV2FPT0WU
NCI-H2107 NF21dllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXDe3k6UUN3ME20N{41QDR4IN88US=> Mk\rV2FPT0WU
NEC8 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1znc2lEPTB;NESuN|M3KM7:TR?= NF3NdVFUSU6JRWK=
COLO-684 NUnvSmJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XNR2lEPTB;NE[uNlI2QCEQvF2= NVfpW3RCW0GQR1XS
LS-411N MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS2XIRKSzVyPUS4MlQ4PDhizszN NWiyNlFLW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
+ 展开
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
储存条件 powder
in solvent
别名 BMS-354825

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Not yet recruiting Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic December 2019 Phase 1|Phase 2
NCT04115059 Not yet recruiting Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 2019 Phase 1
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2
NCT03193281 Recruiting Chronic Myeloid Leukemia University of Auckland New Zealand|Leukaemia & Blood Cancer New Zealand July 17 2017 Phase 2
NCT03041701 Recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID